PMGC Holdings ELAB
NASDAQ ELAB
$4.62 +0.00 (+0.00%)
As of: Sep 10, 2026 · 9:30 AM EDT

PMGC Holdings (ELAB) Non Operating Interest Expenses (2022 - 2026)

PMGC Holdings' (ELAB) quarterly Non Operating Interest Expenses came in at $582241.0 in Q2 2026, up 22.79% quarter-over-quarter from $474170.0 in Q1 2026.

Analysis

PMGC Holdings (ELAB) Non Operating Interest Expenses (2022 - 2026) Analysis & Trends

PMGC Holdings has disclosed Non Operating Interest Expenses across 5 years of filings, most recently posting $582241.0 for Q2 2026.

  • In Q2 2026, Non Operating Interest Expenses changed N/A year-over-year to $582241.0; the TTM figure through Jun 2026 stood at $1.3 million (changed N/A YoY), while the FY2025 annual figure was $257630.0, changed N/A from the prior year.
  • Non Operating Interest Expenses came in at $582241.0 for Q2 2026 at PMGC Holdings, up from $474170.0 in the prior quarter.
  • In the past five years, Non Operating Interest Expenses ranged from a high of $648332.0 in Q3 2024 to a low of -$2.6 million in Q4 2022.
  • Average Non Operating Interest Expenses over 5 years is $2790.6, with a median of $78151.0 recorded in 2025.
  • Year-over-year, Non Operating Interest Expenses slumped 99.12% in 2023 and surged 11248.36% in 2024.
  • Over 5 years, Non Operating Interest Expenses stood at -$2.6 million in 2022, then jumped by 100.26% to $6767.0 in 2023, then jumped by 9480.79% to $648332.0 in 2024, then tumbled by 87.95% to $78151.0 in 2025, then jumped by 645.02% to $582241.0 in 2026.
  • Per Business Quant data, the three most recent Non Operating Interest Expenses figures were $582241.0 in Q2 2026, $474170.0 in Q1 2026, and $78151.0 in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Amgen 209.77 Bn 195.78 Bn 7.24 Bn 673.00 Mn
2 Gilead Sciences 180.17 Bn 176.99 Bn 6.22 Bn 247.00 Mn
3 Vertex Pharmaceuticals 131.81 Bn 123.96 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 82.07 Bn 74.07 Bn 3.93 Bn 11.00 Mn
5 Argenx Se 61.31 Bn 56.12 Bn 1.37 Bn -1.00 Mn
6 Moderna 53.58 Bn 48.44 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 33.65 Bn 30.34 Bn 992.69 Mn 82.05 Mn
8 Biogen 31.73 Bn 30.44 Bn 1.96 Bn -
9 Roivant Sciences 29.65 Bn 29.65 Bn 1.16 Mn -
10 PMGC Holdings 2.25 Mn -16.54 Mn 385,691.00 582,241.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 582,241.00
Mar 31, 2026 474,170.00
Dec 31, 2025 78,151.00
Sep 30, 2025 179,479.00
Sep 30, 2024 648,332.00
Jun 30, 2024 30,806.00
Dec 31, 2023 6,767.00
Sep 30, 2023 5,713.00
Jun 30, 2023 4,409.00
Dec 31, 2022 -2.63 Mn
Sep 30, 2022 646,000.00